Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
Jeffery H. Moran
High Impact
Assistant Professor
Also affiliated: Chonnam National University (2010); Arkansas Children's Hospital (2011–2021); University of Helsinki (2009); Washington University in St. Louis (2009); University of Michigan (2012); Cayman Chemical (United States) (2012); Lickenbrock (2022); Michigan Medicine (2012); Arkansas State Crime Laboratory (2011–2012); Arkansas Department of Health (2007–2018)
Pharmacology & Toxicology, College of Medicine
30 h-index
76 pubs
3,785 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jeffery H. Moran studies the pharmacology and toxicology of abused substances, with a particular focus on synthetic cannabinoids commonly found in products such as K2 and Spice.
His research investigates the mechanisms underlying the toxicity of these compounds, differentiating their effects from those of naturally occurring cannabinoids like Δ9-THC. Moran has examined the metabolism of synthetic cannabinoids, identifying cytochrome P450 enzymes responsible for their oxidative breakdown and characterizing the resulting metabolites, some of which retain significant cannabinoid receptor activity. His work has also addressed the clinical implications of synthetic cannabinoid use, including documented cases of severe toxicity and acute kidney injury.
Moran collaborates with several researchers at the University of Arkansas for Medical Sciences, including Laura P. James and William E. Fantegrossi. His scholarly output includes 83 publications with 3,794 citations, and he has an h-index of 29. He is designated as a highly cited researcher.
Metrics
- h-index: 30
- Publications: 76
- Citations: 3,785
Positions
-
Assistant Professor publications 1996–2026University of Arkansas for Medical Sciences Pharmacology & Toxicology, College of Medicine Institutional directory
Selected Publications
-
Interoceptive effects of N1-substituted lysergamides in rats: Role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide (2026)
-
Co-occurring substance use disorders and the compounding effect of kratom on serious mental illness, US, 2021–2023 (2026)
-
Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses (2026)
-
Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption (2025)
-
Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice (2025)
-
Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Development of a clinical and translational research curriculum for undergraduate students (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)
-
Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)
-
The Spice of Death (2021)
-
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis (2021)
-
55715 Quantification of Neonatal THC Exposure Following Prenatal Marijuana Use (2021)
-
Modifying laboratory testing via home brew during the COVID-19 pandemic (2021)
-
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome (2019)
Grants & Funding
As listed on this researcher's institutional profile.
- Reduced Temperature Thermal Ablation for HCC and other Liver Tumors NIH Co-Investigator
- Metabolomics of menthol cigarette smoking and risk for aggressive prostate cancer among African-American men US Department of Defense Principal Investigator
- HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial Clinical Site NIH Co-Investigator
- Synthetic Cannabinoid Toxicity: Role of Biotransformation NIH Co-Investigator
Collaboration Network
Top Collaborators
William E. Fantegrossi
University of Arkansas Medical Center
17 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
Showing 5 of 17 shared publications
Laura P. James
University of Arkansas for Medical Sciences
16 shared publications
In database
- Severe Toxicity Following Synthetic Cannabinoid Ingestion
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
Showing 5 of 16 shared publications
Paul L. Prather
University of Arkansas for Medical Sciences
14 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
Showing 5 of 14 shared publications
Anna Radomińska‐Pandya
University of Arkansas for Medical Sciences
13 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
Showing 5 of 13 shared publications
Lisa K. Brents
University of Arkansas for Medical Sciences
11 shared publications
In database
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors
- A Major Glucuronidated Metabolite of JWH-018 Is a Neutral Antagonist at CB1 Receptors
Showing 5 of 11 shared publications
Gregory W. Endres
nPoint (United States) (US)
10 shared publications
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- Solid-Phase Extraction and Quantitative Measurement of Omega and Omega-1 Metabolites of JWH-018 and JWH-073 in Human Urine
- A Major Glucuronidated Metabolite of JWH-018 Is a Neutral Antagonist at CB1 Receptors
Showing 5 of 10 shared publications
Amy Patton
9 shared publications
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
- Quantitative Measurement of Acetyl Fentanyl and Acetyl Norfentanyl in Human Urine by LC-MS/MS
- Targeted Metabolomic Approach for Assessing Human Synthetic Cannabinoid Exposure and Pharmacology
- In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome
Showing 5 of 9 shared publications
Kathryn A. Seely
Arkansas Department of Health (US)
9 shared publications
- Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- A Major Glucuronidated Metabolite of JWH-018 Is a Neutral Antagonist at CB1 Receptors
Showing 5 of 9 shared publications
Cindy L. Moran
Arkansas Children's Hospital (US)
8 shared publications
- Severe Toxicity Following Synthetic Cannabinoid Ingestion
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
Showing 5 of 8 shared publications
Donald M. Mock
University of Arkansas for Medical Sciences
6 shared publications
In database
- Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans
- Urinary Excretion of 3-Hydroxyisovaleric Acid and 3-Hydroxyisovaleryl Carnitine Increases in Response to a Leucine Challenge in Marginally Biotin-Deficient Humans
- Quantitative Measurement of Plasma 3-Hydroxyisovaleryl Carnitine by LC-MS/MS as a Novel Biomarker of Biotin Status in Humans
- Urinary Excretion of 3-Hydroxyisovaleryl Carnitine Is an Early and Sensitive Indicator of Marginal Biotin Deficiency in Humans,
- Quantitative Measurement of Urinary Excretion of 3-Hydroxyisovaleryl Carnitine by LC−MS/MS as an Indicator of Biotin Status in Humans
Showing 5 of 6 shared publications
Shawna L. Stratton
University of Arkansas for Medical Sciences (US)
6 shared publications
- Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans
- Urinary Excretion of 3-Hydroxyisovaleric Acid and 3-Hydroxyisovaleryl Carnitine Increases in Response to a Leucine Challenge in Marginally Biotin-Deficient Humans
- Quantitative Measurement of Plasma 3-Hydroxyisovaleryl Carnitine by LC-MS/MS as a Novel Biomarker of Biotin Status in Humans
- Urinary Excretion of 3-Hydroxyisovaleryl Carnitine Is an Early and Sensitive Indicator of Marginal Biotin Deficiency in Humans,
- Quantitative Measurement of Urinary Excretion of 3-Hydroxyisovaleryl Carnitine by LC−MS/MS as an Indicator of Biotin Status in Humans
Showing 5 of 6 shared publications
Thomas D. Horvath
University of Arkansas for Medical Sciences (US)
6 shared publications
- Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans
- Urinary Excretion of 3-Hydroxyisovaleric Acid and 3-Hydroxyisovaleryl Carnitine Increases in Response to a Leucine Challenge in Marginally Biotin-Deficient Humans
- Quantitative Measurement of Plasma 3-Hydroxyisovaleryl Carnitine by LC-MS/MS as a Novel Biomarker of Biotin Status in Humans
- Urinary Excretion of 3-Hydroxyisovaleryl Carnitine Is an Early and Sensitive Indicator of Marginal Biotin Deficiency in Humans,
- Quantitative Measurement of Urinary Excretion of 3-Hydroxyisovaleryl Carnitine by LC−MS/MS as an Indicator of Biotin Status in Humans
Showing 5 of 6 shared publications
Anna Bogusiewicz
University of Arkansas for Medical Sciences (US)
6 shared publications
- Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans
- Urinary Excretion of 3-Hydroxyisovaleric Acid and 3-Hydroxyisovaleryl Carnitine Increases in Response to a Leucine Challenge in Marginally Biotin-Deficient Humans
- Quantitative Measurement of Plasma 3-Hydroxyisovaleryl Carnitine by LC-MS/MS as a Novel Biomarker of Biotin Status in Humans
- Urinary Excretion of 3-Hydroxyisovaleryl Carnitine Is an Early and Sensitive Indicator of Marginal Biotin Deficiency in Humans,
- Quantitative Measurement of Urinary Excretion of 3-Hydroxyisovaleryl Carnitine by LC−MS/MS as an Indicator of Biotin Status in Humans
Showing 5 of 6 shared publications
David F. Grant
University of Arkansas for Medical Sciences (US)
6 shared publications
- Analysis of the Cytotoxic Properties of Linoleic Acid Metabolites Produced by Renal and Hepatic P450s
- Cytotoxicity of Linoleic Acid Diols to Renal Proximal Tubular Cells
- Analysis of the Toxic Effects of Linoleic Acid, 12,13-cis-Epoxyoctadecenoic Acid, and 12,13-Dihydroxyoctadecenoic Acid in Rabbit Renal Cortical Mitochondria
- Defining Mechanisms of Toxicity for Linoleic Acid Monoepoxides and Diols in Sf-21 Cells
- Linoleic acid, cis-epoxyoctadecenoic acids, and dihydroxyoctadecadienoic acids are toxic to Sf-21 cells in the absence of albumin
Showing 5 of 6 shared publications
Krishna C. Chimalakonda
University of Arkansas for Medical Sciences (US)
6 shared publications
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
- Solid-Phase Extraction and Quantitative Measurement of Omega and Omega-1 Metabolites of JWH-018 and JWH-073 in Human Urine
- Conjugation of Synthetic Cannabinoids JWH-018 and JWH-073, Metabolites by Human UDP-Glucuronosyltransferases
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Lauren N. Russell
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cannabis and Cannabinoid Research
Substance Abuse Treatment and Outcomes
Kirsten Clement
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cannabis and Cannabinoid Research
Metabolomics and Mass Spectrometry Techniques
Lirit N. Franks
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cannabis and Cannabinoid Research
Substance Abuse Treatment and Outcomes
William E. Fantegrossi
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cannabis and Cannabinoid Research
Substance Abuse Treatment and Outcomes
Laura K. Schnackenberg
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Metabolomics and Mass Spectrometry Techniques
Drug-Induced Hepatotoxicity and Protection
Jinchun Sun
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Metabolomics and Mass Spectrometry Techniques
Drug-Induced Hepatotoxicity and Protection